For example, the T315I mutation of ABL1 in leukemia cells reduces the efficacy of imatinib (Jabbour et al., 2008), and LIGHTHOUSE accurately predicted the effect of this mutation (Figure 5C). This evidence concerns the gene ABL1 and leukemia.